Specialist & Consultant Medical Microbiology oral assessment prep

Knowledge: This is MRSA bacteraemia, almost certainly catheter-related, and Staphylococcus aureus in blood is never a contaminant. With a prosthetic valve the risk of endocarditis is high, and the bacteraemia cannot be called uncomplicated until endocarditis is excluded. Cefazolin does not cover MRSA, so therapy should change to vancomycin dosed around dialysis to an AUC target, or daptomycin if response or MIC is a concern. Guidelines advise removing a long-term catheter infected with Staphylococcus aureus, because salvage has a high failure rate. Treatment is at least 14 days for uncomplicated bacteraemia and 6 weeks with combination therapy for prosthetic valve endocarditis.

Management: I would phone the renal consultant now to switch to vancomycin with a weight-based loading dose and pharmacy-guided levels. I would advise removing the tunnelled catheter within 24 hours, with temporary access at a new site and a new tunnelled line once cultures are negative. I would ask for repeat blood cultures every 48 to 72 hours until negative and a transoesophageal echocardiogram, because transthoracic echo is insufficient with a prosthetic valve. I would advise looking for metastatic foci if he has spinal or joint pain. I would ensure contact precautions in the dialysis unit. I would document my advice in the record and recommend infectious diseases and cardiology review.

Ethics and communication: The decision about the catheter should be explained to the patient, who needs to understand why losing his line is safer though inconvenient. My advice must be written in the notes, not only given by phone. If the team keeps the catheter against advice, I would document the disagreement and escalate to the clinical director, because the mortality risk is significant.

Reference: IDSA Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection (2009); IDSA Clinical Practice Guidelines for the Treatment of MRSA Infections (2011); ESC Guidelines for the Management of Endocarditis (2023)

Knowledge: Four linked cases of the same organism and carbapenemase in one unit in under two weeks should be managed as an outbreak until proven otherwise. OXA-48-like enzymes are common in the region and may give only modest carbapenem MICs, so screening thresholds and molecular confirmation matter. Transmission is mainly through staff hands, shared equipment and the environment, including sinks and drains. Typing, ideally whole genome sequencing, confirms relatedness, but control measures should not wait for it. Current IDSA guidance prefers ceftazidime-avibactam for OXA-48 producers and does not suggest meropenem-vaborbactam or imipenem-relebactam.

Management: I would declare a suspected outbreak to the infection prevention lead today and convene an outbreak control team with ICU, nursing, pharmacy, environmental services and management. I would introduce contact precautions, cohort cases with dedicated staff, and audit hand hygiene and equipment cleaning. I would screen all current ICU patients now and weekly, and screen transfers from abroad on admission. I would confirm the carbapenemase gene in all isolates, send them for typing and consider environmental sampling of sinks. I would advise ceftazidime-avibactam for the bloodstream infections, with renal dose adjustment and source control. I would keep a line list and epidemic curve, inform management and report to the health authority as it requires. The outbreak is closed only after a defined period without new cases.

Ethics and communication: Patients and families should be told that the patient carries a resistant organism and why precautions are needed, without stigma. Isolation must not reduce the quality of care, which is a known risk. Reporting supports public health, and I would share only necessary data, consistent with Federal Law No. 2 of 2019. If transmission reflects a practice lapse, the review should focus on systems rather than individuals.

Reference: WHO Guidelines for the Prevention and Control of Carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in Health Care Facilities (2017); IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections

Knowledge: Gram-negative diplococci in CSF with a petechial rash make Neisseria meningitidis the working diagnosis, with meningitis and septicaemia. Umrah and Hajj travel is a recognised risk, and past serogroup W135 outbreaks among pilgrims led to quadrivalent conjugate vaccine requirements. Pretreatment lowers culture yield quickly, so PCR on CSF and EDTA blood is important for confirmation and serogrouping. Ceftriaxone 2 g every 12 hours is appropriate, usually for about 7 days, and dexamethasone is generally stopped once meningococcus is confirmed. Close contacts need chemoprophylaxis, and laboratory-acquired meningococcal disease has a high fatality rate.

Management: I would phone the clinical team immediately with the Gram stain, advise continuing ceftriaxone and support ICU review for septic shock. I would send CSF and blood for meningococcal PCR and keep any isolate for the reference laboratory. I would advise droplet precautions for the first 24 hours of effective treatment. I would notify the case to the public health authority the same day, so contact tracing and prophylaxis such as single-dose ciprofloxacin can start. Healthcare workers need prophylaxis only after unprotected exposure to respiratory secretions, such as during intubation. I would confirm that any culture was handled in a biosafety cabinet and offer prophylaxis to exposed laboratory staff if it was not.

Ethics and communication: Notification is a legal duty under Federal Law No. 14 of 2014, and I would share only what contact tracing needs. Family and contacts need clear information about prophylaxis without panic or blame. While his consciousness is impaired, emergency treatment proceeds without delay and the family is kept informed. I would document the times of results, calls and notification.

Reference: ESCMID Guideline: Diagnosis and Treatment of Acute Bacterial Meningitis (2016); IDSA Practice Guidelines for the Management of Bacterial Meningitis (2004); Federal Law No. 14 of 2014 on the Prevention of Communicable Diseases (UAE)

Knowledge: Brucella species are Risk Group 3 organisms, and brucellosis is the most commonly reported laboratory-associated bacterial infection, spread by aerosols at very low infectious doses. Manipulating cultures on the open bench, and especially sniffing plates, is a high-risk exposure, while being in the room at a distance is lower risk. CDC advises at least 21 days of doxycycline with rifampicin for high-risk exposures, with symptom and serological monitoring for 24 weeks. Doxycycline is avoided in pregnancy, so an alternative regimen is chosen with specialist advice. A slow-growing small Gram-negative coccobacillus from a patient with livestock or camel milk exposure should trigger biosafety cabinet handling before identification.

Management: I would stop open-bench work, move all cultures into a biosafety cabinet with containment level 3 practice if available, and decontaminate the area. I would list everyone present and classify each as high or low risk by activity and distance. High-risk staff would see occupational health the same day for baseline serology and prophylaxis, with an obstetric and infectious diseases plan for the pregnant scientist. Low-risk staff would have symptom and serological follow-up. I would notify the patient's brucellosis to the health authority and advise clinicians on treatment and on imaging for spondylitis. I would report the exposure as an incident and require that positive bottles from patients with animal exposure be handled in a cabinet, with a strict no-sniffing rule.

Ethics and communication: I owe a duty of care to staff as well as patients, and I would explain risks and options honestly, including the uncertainties in pregnancy. Her pregnancy is confidential and shared only with those who need it. Prophylaxis is offered, not imposed, and her choice is documented. The review should be fair to scientists who acted without knowing the risk.

Reference: CDC Biosafety in Microbiological and Biomedical Laboratories (6th ed, 2020); WHO Laboratory Biosafety Manual (4th ed, 2020); Federal Law No. 14 of 2014 on the Prevention of Communicable Diseases (UAE)

Knowledge: Severe respiratory illness with camel exposure in the Arabian Peninsula makes MERS-CoV a priority diagnosis, alongside bacterial pneumonia, influenza and Legionella. Diabetes and chronic kidney disease increase the risk of severe disease. The virus replicates mainly in the lower respiratory tract, so a negative nasopharyngeal swab does not exclude it, and WHO prefers lower respiratory specimens, with upper tract samples added where possible. WHO guidance uses an upE RT-PCR screen with confirmation by a second target such as ORF1a. Delayed recognition and aerosol-generating procedures have driven large hospital outbreaks in the region.

Management: I would advise moving him now to a single room, ideally an airborne infection isolation room, with gowns, gloves, eye protection and respirators for aerosol-generating procedures such as high-flow oxygen. I would ask for sputum or tracheal aspirate plus a nasopharyngeal swab for MERS-CoV RT-PCR, packed and labelled as required and processed in a biosafety cabinet. I would notify the suspected case to the public health authority immediately, without waiting for the result. I would advise empirical treatment for pneumonia and influenza, as there is no proven specific antiviral therapy. I would start a list of exposed staff and patients from the open bay. If the first test is negative but suspicion remains, I would repeat lower respiratory sampling.

Ethics and communication: Isolation restricts his freedom but is justified by a serious public health risk, and he and his family should be told why. Notification is a legal duty under Federal Law No. 14 of 2014, sharing only necessary data. Staff have a right to adequate protective equipment, and I would escalate shortages. Media communication belongs to the authority, not to me.

Reference: WHO Laboratory Testing for Middle East Respiratory Syndrome Coronavirus: Interim Guidance (2018); WHO Laboratory Biosafety Manual (4th ed, 2020); Federal Law No. 14 of 2014 on the Prevention of Communicable Diseases (UAE)

Knowledge: A single positive culture from a smear-negative, PCR-negative specimen processed next to a strongly positive sample, with identical genomes, strongly suggests laboratory cross-contamination. Clues include one positive among negatives, long time to positivity and low colony counts. An epidemiological link between the two patients must be excluded before concluding contamination. Mechanisms include aerosols during processing, shared reagents and carry-over in equipment. ISO 15189 requires investigation, corrective action and correction of issued reports.

Management: I would discuss the evidence with her treating physician today and agree that a false-positive culture is most likely, while checking for any contact between the two patients. I would advise stopping antituberculous drugs given the hepatitis and the likely false result, with liver monitoring. I would issue an amended report explaining that the culture is considered probable cross-contamination, and inform the public health authority so the notification is corrected and contact tracing stopped. I would open an incident and review batch order, cabinet practice, reagent aliquoting and centrifuge use. I would introduce processing of smear-negative samples before known positives, single-use aliquots and consultant review of isolated positives before release. I would look back for similar events.

Ethics and communication: She has been harmed, lost work and may have faced stigma, so she deserves an early, honest explanation and apology from the treating team and me. I would offer to meet her and, with her consent, provide a letter clearing her for work. Correcting the notification is necessary and confidential. The case may be reviewed under Federal Decree-Law No. 4 of 2016 on Medical Liability, and I would cooperate openly.

Reference: WHO Consolidated Guidelines on Tuberculosis: Module 3: Diagnosis; ISO 15189:2022 Medical Laboratories: Requirements for Quality and Competence; Federal Decree-Law No. 4 of 2016 on Medical Liability (UAE)